The global antihypertensive market accounted for $22,557 million in 2018, and is expected to reach $28,797 million by 2026, registering a CAGR of 3.1% from 2019 to 2026. Antihypertensive drugs are employed for the treatment of patients suffering from hypertension. Hypertension is a medical condition, which involves rise in blood pressure in the arteries. Furthermore, the patient suffering from hypertension is highly susceptible to other complications, which include heart failure and aneurysm. Therefore, the treatment of this medical condition requires early diagnosis and management by the use of antihypertensive drugs. Some of the antihypertensive drugs available in the market include beta blockers, calcium channel blockers, and vasodilators. These drugs are prescribed by a physician, and are available in retail stores and hospital pharmacies.
The growth of the global antihypertensive market is driven by a surge in incidence of hypertension across the globe. Furthermore, rise in awareness related to complications associated with hypertension is another major factor that fuels the growth of the market. Moreover, increase in geriatric population and sedentary lifestyle act as key drivers of the global market. However, recent patent expirations hinder the growth of the antihypertensive market. Conversely, a surge in research related to antihypertensive drugs in emerging economies is expected to offer lucrative opportunities during the forecast period.
The global antihypertensive market size is segmented into therapeutic class, distribution channel, and region. On the basis of therapeutic class, the market is fragmented into diuretics, ACE inhibitors, calcium channel blockers, vasodilators, beta-adrenergic blockers, and others. Depending on distribution channel, it is segregated into retail pharmacy, hospital pharmacy, and e-commerce. Region wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
Key Market Segments
By Distribution Channel
By Region
LIST of key players profiled in the report
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
The global antihypertensive market size is segmented into therapeutic class, distribution channel, and region. On the basis of therapeutic class, the market is fragmented into diuretics, ACE inhibitors, calcium channel blockers, vasodilators, beta-adrenergic blockers, and others. Depending on distribution channel, it is segregated into retail pharmacy, hospital pharmacy, and e-commerce. Region wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
- This report entails a detailed quantitative analysis along with the current global antihypertensive market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
- The market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
- By Therapeutic Class
- Diuretics
- ACE Inhibitors
- Calcium Channel Blockers
- Beta-adrenergic Blockers
- Vasodilators
- Others
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- E-commerce
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
LIST of key players profiled in the report
- Boehringer Ingelheim GmbH
- Merck KGaA
- Johnson and Johnson
- Bayer AG
- Pfizer, Inc.
- Takeda Pharmaceutical Co., Ltd.
- AstraZeneca plc
- Daiichi Sankyo Company
- Sanofi S.A.
- Novartis International AG
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
- Merck
- United Therapeutics Corporation Safe In Breastfeeding
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Overview
Chapter 4: Antihypertensive Drugs Market, By Drug Class
Chapter 5: Antihypertensive Drugs Market, By End User
Chapter 6: Antihypertensive Drugs Market, By Region
Chapter 7: Company Profiles
Executive Summary
According to the report titled, 'Antihypertensive Drugs Market by Therapeutic Class and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019-2026', the global antihypertensive drugs market was valued at $22 billion in 2018, and is expected to reach $28 billion by 2026, registering a CAGR of 3.1% from 2019 to 2026.Hypertension is a long-term medical condition, which is marked by the rise in blood pressure. Blood pressure is considered higher than normal when the systolic blood pressure is more than 140mm Hg or the diastolic blood pressure is more than 90 mm Hg. Moreover, this medical condition is accompanied with other complications such as dementia, heart failure, and kidney diseases. Therefore, this condition requires an early diagnosis and treatment. The drugs employed in the treatment of this condition are termed as antihypertensive. Different type of the antihypertensive drugs available in the market include calcium channel blockers and vasodilators.
The factors that significantly contribute toward the growth of the global antihypertensive drugs market include a surge in incidence of hypertension across the globe. Furthermore, rise in awareness related to complications associated with hypertension acts as a major factor that fuels the growth of the market. Moreover, increase in geriatric population and sedentary lifestyle boost the growth of the market. However, recent patent expirations hinder the growth of the antihypertensive drugs market. On the contrary, a surge in research related to antihypertensive drugs is expected to offer lucrative opportunities during the forecast period.
The global antihypertensive drugs market is studied on the basis of therapeutic class, distribution channel, and region to provide a detailed assessment of the market. Depending on therapeutic class, the market is divided into diuretics, ACE inhibitors, calcium channel blockers, vasodilators, beta-adrenergic blockers, and others. By distribution channel, it is categorized into retail pharmacy, hospital pharmacy, and e-commerce. Region wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA). According to therapeutic class, the calcium channel blockers segment occupied the largest share in 2018, owing to lesser side effects exhibited by these drugs as compared to the other type of antihypertensive drugs. However, the ACE inhibitors segment is expected to grow at the fastest rate during the forecast period, due to benefits offered such as positive impact on overall health and decrease in progression of kidney diseases.
By distribution channel, the hospitals segment occupied the largest share, due to rise in number of hospitals worldwide. Furthermore, antihypertensive drugs are prescription-based medications, which are mostly prescribed by the specialized healthcare professionals available in hospitals, thereby propelling the growth of this segment. Conversely, the e-commerce segment is expected to exhibit the fastest growth rate during the forecast period, owing to a surge in the use of internet across the globe.
In 2018, North America accounted for the major share in the antihypertensive drugs market, owing to easy availability of these drugs. Moreover, a surge in incidence of hypertension and rise in geriatric population act as the key drivers of the market in this region. However, Asia-Pacific is projected to register the fastest growth during the forecast period, owing to a surge in awareness related to the use of antihypertensive drugs. Furthermore, a surge in research related to antihypertensive drugs in developing economies is anticipated to offer lucrative opportunities for antihypertensive providers to expand their business. In addition, the constantly evolving life science industry drives the growth of the market in the developing economies such as India and China.
Key findings of the study:
Calcium channel blockers occupied one-fourths share of the global antihypertensive drugs market in 2018.
The ACE inhibitors segment is anticipated to grow with the highest CAGR throughout the forecast period.
The vasodilators accounted for more than one-fifths share of the market in 2018.
Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.'
Companies Mentioned
- Boehringer Ingelheim GmbH
- Merck KGaA
- Johnson and Johnson
- Bayer AG
- Pfizer Inc. Takeda Pharmaceutical Co. Ltd.
- AstraZeneca plc
- Daiichi Sankyo Company
- Sanofi S.A.
- Novartis International AG.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
